Audiologists in Lawton, OK Accepting Medicare
5 Audiologists found. Showing 1 - 5
 Dr. Tyler Tate Bay, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1515 Ne Lawrie Tatum Rd, Lawton, OK 73507 Phone: 580-354-5115 Fax: 580-354-5118 |
 Michele L Rogers, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 4920 Sw Lee Blvd, Lawton, OK 73505 Phone: 580-536-8844 Fax: 580-536-8818 |
Shane Dollarhite, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 4404 Nw Cache Rd, Ste 4, Lawton, OK 73505 Phone: 580-357-0400 |
Dr. Marshall Krizoa Nguessan, AUD. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1102 Se 36th St, Ste B, Lawton, OK 73501 Phone: 580-351-2278 Fax: 580-353-0462 |
Sharly Michelle Hooper, M .S.,CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: Usphs Indian Hospital, 1515 Lawrie Tatum Rd, Lawton, OK 73507 Phone: 580-354-5117 Fax: 580-354-5116 |
News Archive
Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses
A new study released on the bioRxiv* server compared the antibodies produced in young patients with these three conditions against the two immunodominant coronavirus antigens, the spike and the nucleocapsid antigens.
FDA approves Alexion's Soliris drug for treatment of atypical hemolytic uremic syndrome
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Study focuses on two natural approaches to preventing breast cancer
Preventing cancer requires intimate knowledge of how cancer starts, what causes it to grow and flourish, and how to stop it in its tracks. Sometimes this comes in the form of a vaccine (the HPV vaccine for cervical and head and neck cancers), a screening (a colonoscopy for colorectal cancer) or a blood test (the PSA level test for prostate cancer).
AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test.
› Verified 8 days ago
Physical Therapists
Speech-Language Pathologists
Optometrists
Chiropractors
Occupational Therapists
Podiatrists
Audiologists